Indications for: SYMJEPI
Emergency treatment of allergic reactions (Type 1) including anaphylaxis.
Adults and Children:
Give by IM or SC inj into the anterolateral aspect of the thigh only. 15–30kg: 0.15mg. ≥30kg: 0.3mg. May repeat another dose if needed.
The presence of sulfite in this product should not deter use. Cardiovascular disease. Hypertension. Hyperthyroidism. Diabetes. Parkinson’s disease. Injection-related complications: do not inject intravenously or into buttock (risk of Clostridium infection), digits, hands, or feet; hold leg firmly and limit movement in children prior to and during injection. Advise patient to seek medical help immediately. Train patient in use of device. Elderly. Pregnancy. Nursing mothers.
May be potentiated by MAOIs, tricyclic antidepressants, levothyroxine, antihistamines (eg, chlorpheniramine, tripelennamine, diphenhydramine). May be antagonized by β-blockers (eg, propranolol), α-blockers (eg, phentolamine), ergot alkaloids. Arrhythmias possible with cardiac glycosides, diuretics, or anti-arrhythmics.
Anxiety, apprehensiveness, restlessness, tremor, weakness, dizziness, sweating, palpitations, pallor, nausea, vomiting, headache, respiratory difficulties; arrhythmias, angina pectoris; rare: serious skin and soft tissue infections at inj site, stress cardiomyopathy.
Generic Drug Availability: